Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
NEW YORK, Jan. 29, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased GW Pharmaceuticals plc (Nasdaq:GWPH) securities between December 4, 2014 and January 8, 2016.
Click here to learn about the case: http://docs.wongesq.com/GWPH-Info-Request-Form-1080. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company lacked effective internal financial controls; (ii) the Company lacked effective controls over completeness and valuation of clinical trial accruals; and (iii) as a result of the foregoing, Defendants’ statements about GW Pharmaceuticals’ business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
In its 2015 Annual Report, GW Pharmaceuticals disclosed the discovery of a material weakness in its internal control over financial reporting for the year ended September 30, 2015. The Company noted that “management does not have sufficiently precise controls to evaluate the completeness and accuracy of the calculation of clinical trial accruals due to the incorrect allocation of expenditure to clinical studies.” On this news, GW Pharmaceuticals stock fell $3.55, or nearly 6%, to close at $56.31 per share on January 11, 2016.
If you suffered a loss in GW Pharmaceuticals you have until March 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/GWPH-Info-Request-Form-1080.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigation involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
